Apical Hypertrophic Cardiomyopathy in a Case with Chest Pain and Family History of Sudden Cardiac Death: A Case Report

Document Type: Case Report

Authors

Cardiologist, Division of Cardiovascular, Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which is caused by a multitude of mutations in genes encoding proteins of the cardiac sarcomere (1). Apical hypertrophic cardiomyopathy (AHCM) is an uncommon type of HCM. The sudden cardiac death is less likely to occur in the patients inflicted with AHCM (2). Herein, we presented the case of a 29-year-old man with AHCM, who had typical exertional chest pain without any cardiovascular risk factors, except for a sudden cardiac death in his older brother at the age of 28 years. After performing complete clinical and paraclinical evaluations, the patient underwent optimal medical treatment with beta-blocker agents without any symptoms.

Keywords


  1. Maron BJ, McKenna WJ, Danielson GK, Kappen-berger LJ, Kuhn HJ, Seidman CE, et al. American college of cardiology/European society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American college of cardiology foundation task force on clinical expert consensus documents and the European society of cardiology committee for practice guidelines. J Am Coll Cardiol. 2003; 42:1687-713.
  2. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003; 92:1183-6.
  3. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008; 19:104-10.
  4. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of gene testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009; 54:201-11.
  5. Maron BJ, Seidman CE, Ackerman MJ, Towbin JA, Maron MS, Ommen SR, et al. How should hypertrophic cardiomyopathy be classified? What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet. 2009; 2:81-5.
  6. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009; 119:1085-92.
  7. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008; 52:559-66.
  8. Moukarbel GV, Alam SE, Abchee AB. Contrast-enhanced echocardiography for the diagnosis of apical hypertrophic cardiomyopathy. Echocardio-graphy. 2005; 22:831-3.
  9. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working group. Circulation. 2006; 113:1807-16.